| Literature DB >> 34978535 |
Silvina Catuara-Solarz1, Bartlomiej Skorulski1, Iñaki Estella-Aguerri1, Claudia Bibiana Avella-Garcia1, Sarah Shepherd1, Emily Stott1, Nicola R Hemmings1, Aleix Ruiz de Villa1, Laura Schulze1, Sophie Dix1.
Abstract
BACKGROUND: Against a long-term trend of increasing demand, the COVID-19 pandemic has led to a global rise in common mental disorders. Now more than ever, there is an urgent need for scalable, evidence-based interventions to support mental well-being.Entities:
Keywords: COVID-19; anxiety; cognitive behavioral therapy; digital health; health app; insomnia; mental health; mental well-being; mobile app; positive psychology
Mesh:
Year: 2022 PMID: 34978535 PMCID: PMC9255362 DOI: 10.2196/30976
Source DB: PubMed Journal: JMIR Mhealth Uhealth ISSN: 2291-5222 Impact factor: 4.947
Figure 1Overview of the study design. PSS-10: 10-item Perceived Stress Score; ONS-4: Office of National Statistics Four Subjective Well-being Questions; GAD-7: 7-item Generalized Anxiety Disorder scale; WHO-5: World Health Organization-5 Well-Being Index; CD-RISC: Connor-Davidson Resilience Scale; MISS: Minimal Insomnia Scale.
Figure 2Screenshots of the Foundations app.
Activity formats and descriptions of the content delivered in Foundations.
| Activity | Number of activities | Type of content | Description |
| Slides | 12 | Psychoeducation | Comprises individual screens of 1-2 sentences that the user swipes through. Usually 10-20 screens |
| Article/blog | 13 | Psychoeducation and tips | User scrolls through to read. Typically 0.25-1 of A4 page in length |
| Add record | 10 | Journaling/reflection | User can add free text (eg, thought records or gratitude journaling) |
| Label record | 5 | Journaling/reflection | User selects a record created by the “add record” feature and can choose a theme label |
| Question record | 5 | Journaling/reflection | User selects a previous record and is asked a series of questions about the record. There is a free-text box for the user to write in |
| Record review | 4 | Journaling/reflection | Log of record entries |
| Audios | 17 | Mindfulness/meditations | Mindful meditations (5-8 min), sleep meditations (30 min), relaxation techniques |
| Ambient sounds | 8 | Ambient sounds | 30-min relaxation sounds and soundscapes (eg, waves, rain) |
| Quiz | 6 | Interactive psychoeducation | Reinforces psychoeducation with two-choice answers |
| Game | 1 | Spatial working memory game | The user has to recall spatial sequences |
Description of programs and the number of activities within each program.
| Program name | Number of activities | Description |
| Become a breathing master | 3 | Teaches the skill of diaphragmatic breathing |
| Relax your body and mind | 2 | Teaches the skill of progressive muscle relaxation |
| Working with thoughts | 5 | CBTa-based journaling and reflection. Includes psychoeducation on cognitive distortions and questions to balance unhelpful thoughts |
| Positive thinking | 5 | Gratitude journaling on achievements, reasons to be thankful, and people |
| Healthy sleep habits | 9 | CBT psychoeducation on healthy sleep habits and sleep hygiene |
| Break your bad sleep habits | 4 | CBT interactive psychoeducation on breaking bad habits |
| Take control of your sleep | 9 | CBT sleep scheduling |
| Constructive worry for sleep | 4 | Introduces constructive worry to put worries aside before bed |
| 3 days to improve your self-esteem | 10 | CBT-based journaling and psychoeducation on automatic thoughts and balancing thoughts about oneself |
| Boost your confidence | 3 | Identify strengths |
aCBT: cognitive behavioral therapy.
Figure 3CONSORT (Consolidated Standards of Reporting Trials) flowchart of participants. PSS-10: 10-item Perceived Stress Score.
Characteristics of study participants at baseline.
| Characteristic | Foundation group (n=62) | Control group (n=74) | Effect size ( | P value | Clinical interpretation | |
|
| ||||||
|
| Females, n | 33 | 40 | N/Aa | .32 | N/A |
|
| Males, n | 29 | 34 | N/A | .48 | N/A |
| Age (years), mean (SD) | 40.58 (6.08) | 39.49 (6.13) | N/A | .30 | N/A | |
| PSS-10b, mean (SD) | 19.19 (4.12) | 19.05 (3.58) | –0.04 (nc) | 0.58 | moderate stress | |
| GAD-7d, mean (SD) | 8.06 (3.83) | 6.91 (3.28) | –0.32 (small) | 0.97 | mild anxiety | |
| WHO-5e, mean (SD) | 11.35 (4.29) | 12 (4.23) | 0.15 (n) | 0.81 | poor well-being | |
| ONS-4f, mean (SD) | 22.63 (5.14) | 23.64 (5.82) | 0.18 (n) | 0.85 | N/A | |
| CD-RISCg, mean (SD) | 23.27 (5.76) | 24.91 (4.96) | 0.31 (small) | 0.96 | problems in coping with stress or bouncing back from adversity | |
| MISSh, mean (SD) | 4.82 (2.3) | 4.6 (2.51) | –0.09 (n) | 0.7 | no sleep problems | |
aN/A: not applicable.
bPSS-10: 10-item Perceived Stress Score.
cn: negligible or no effect.
dGAD-7: 7-item Generalized Anxiety Disorder scale.
eWHO-5: World Health Organization-5 Well-Being Index.
fONS-4: Office of National Statistics Four Subjective Well-being Questions.
gCD-RISC: Connor-Davidson Resilience Scale.
hMISS: Minimal Insomnia Scale.
Within-group analyses showing the change from baseline on the outcome measures at each time point (week 2 and week 4).
| Outcome measure | Intervention group | Control group | ||||||||||||||||
|
| Mean (SD) | P valuea | Effect size ( | Mean (SD) | P valuea | Effect size ( | ||||||||||||
|
| ||||||||||||||||||
|
| Baseline | 8.06 (3.83) | —c | — | — | 6.92 (3.28) | — | — | — | |||||||||
|
| Week 2 | 6.71 (4.79) | –2.41 | <.001 | –0.31 | 6.69 (3.92) | –0.61 | .27 | –0.06 | |||||||||
|
| Week 4 | 6.02 (4.29) | –3.69 | <.001 | –0.50 | 6.14 (3.88) | –1.92 | .03 | –0.22 | |||||||||
|
| ||||||||||||||||||
|
| Baseline | 4.82 (2.30) | — | — | — | 4.61 (2.51) | — | — | — | |||||||||
|
| Week 2 | 3.66 (2.28) | –3.43 | <.001 | –0.51 | 4.35 (2.61) | –0.96 | .17 | –0.10 | |||||||||
|
| Week 4 | 3.15 (1.90) | –5.31 | <.001 | –0.79 | 4.05 (1.72) | –2.03 | .02 | –0.21 | |||||||||
|
| ||||||||||||||||||
|
| Baseline | 23.27 (5.76) | — | — | — | 24.91 (4.97) | — | — | — | |||||||||
|
| Week 2 | 25.06 (5.47) | 3.45 | <.001 | 0.31 | 24.59 (5.02) | –0.84 | .80 | –0.06 | |||||||||
|
| Week 4 | 25.66 (5.48) | 4.07 | <.001 | 0.42 | 25.19 (5.78) | 0.58 | .28 | 0.05 | |||||||||
|
| ||||||||||||||||||
|
| Baseline | 11.35 (4.29) | — | — | — | 12.00 (4.23) | — | — | — | |||||||||
|
| Week 2 | 12.89 (5.10) | 2.28 | .01 | 0.32 | 11.77 (4.38) | –0.47 | .68 | –0.05 | |||||||||
|
| Week 4 | 13.95 (4.45) | –3.85 | <.001 | 0.59 | 12.12 (4.64) | 0.25 | .40 | 0.03 | |||||||||
|
| ||||||||||||||||||
|
| Baseline | 5.69 (1.53) | — | — | — | 6.08 (1.76) | — | — | — | |||||||||
|
| Week 2 | 6.66 (1.64) | 3.79 | <.001 | 0.61 | 6.69 (3.92) | 1.33 | .09 | 0.15 | |||||||||
|
| Week 4 | 6.95 (1.32) | 5.41 | <.001 | 0.88 | 6.61 (1.57) | 2.60 | .006 | 0.32 | |||||||||
|
| ||||||||||||||||||
|
| Baseline | 6.34 (1.94) | — | — | — | 6.30 (1.70) | — | — | — | |||||||||
|
| Week 2 | 6.82 (1.89) | 1.69 | .05 | 0.25 | 6.42 (1.78) | 0.64 | .26 | 0.07 | |||||||||
|
| Week 4 | 7.06 (1.56) | 2.64 | .005 | 0.41 | 6.59 (1.70) | 1.48 | .07 | 0.17 | |||||||||
|
| ||||||||||||||||||
|
| Baseline | 5.95 (1.51) | — | — | — | 6.16 (1.72) | — | — | — | |||||||||
|
| Week 2 | 6.55 (1.87) | 2.32 | .01 | 0.35 | 6.35 (1.53) | 0.99 | .16 | 0.12 | |||||||||
|
| Week 4 | 7.08 (1.55) | 4.99 | <.001 | 0.74 | 6.47 (1.78) | 1.39 | .08 | 0.18 | |||||||||
|
| ||||||||||||||||||
|
| Baseline | 4.65 (1.66 | — | — | — | 5.09 (2.00) | — | — | — | |||||||||
|
| Week 2 | 5.13 (2.50) | 1.64 | .05 | 0.22 | 5.42 (2.25) | 1.38 | .09 | 0.15 | |||||||||
|
| Week 4 | 5.08 (2.77) | 1.24 | .11 | 0.19 | 5.12 (2.42) | 0.09 | .46 | 0.01 | |||||||||
|
| ||||||||||||||||||
|
| Baseline | 19.19 (4.12) | — | — | — | 19.05 (3.58) | — | — | — | |||||||||
|
| Week 1 | 18.32 (5.27) | –1.35 | .09 | –0.18 | 17.59 (5.03) | –2.95 | .002 | –0.32 | |||||||||
|
| Week 2 | 16.26 (6.20) | –3.38 | <.001 | –0.55 | 17.00 (5.50) | –3.31 | <.001 | –0.43 | |||||||||
|
| Week 3 | 15.65 (5.55) | –4.79 | <.001 | –0.72 | 17.01 (5.93 | –3.04 | .002 | –0.40 | |||||||||
|
| Week 4 | 15.53 (5.82) | –4.86 | <.001 | –0.72 | 16.38 (5.72) | –3.99 | <.001 | –0.55 | |||||||||
aComparisons were made for each time point relative to the baseline level; significance thresholds have been adjusted to account for multiple comparisons (Bonferroni): P<.025 for all outcomes except for PSS-10, which was set to P<.012.
bGAD-7: 7-item Generalized Anxiety Disorder scale.
cnot applicable.
dMISS: Minimal Insomnia Scale.
eCD-RISC-10: Connor-Davidson Resilience Scale.
fWHO-5: World Health Organization-5 Well-Being Index.
gONS-4: Office of National Statistics Four Subjective Well-being Questions.
hPSS-10: 10-item Perceived Stress Score.
Between-group analyses showing the change of outcome measures (Δ) from baseline at each time point (week 2 and week 4).
| Outcome measure | Intervention Δ, mean (SD) | Control Δ, mean (SD) | Mean difference | P value | Effect size ( | |||||||
|
| ||||||||||||
|
| Week 2 | –1.35 (4.43) | –0.23 (3.24) | 1.13 | 1.71 | .04 | 0.29 | |||||
|
| Week 4 | –2.05 (4.37) | –0.78 (3.52) | 1.26 | 1.87 | .03 | 0.32 | |||||
|
| ||||||||||||
|
| Week 2 | –1.16 (2.67) | –0.26 (2.29) | 0.90 | 2.13 | .02 | 0.37 | |||||
|
| Week 4 | –1.68 (2.49) | –0.55 (2.35) | 1.12 | 2.70 | .004 | 0.47 | |||||
|
| ||||||||||||
|
| Week 2 | 1.79 (4.08) | –0.31 (3.16) | –2.10 | –3.37 | <.001 | –0.58 | |||||
|
| Week 4 | 2.39 (4.62) | 0.28 (4.24) | –2.10 | –2.78 | .003 | –0.48 | |||||
|
| ||||||||||||
|
| Week 2 | 1.53 (5.30) | –0.23 (4.20) | –1.76 | –2.16 | .02 | –0.37 | |||||
|
| Week 4 | 2.59 (5.32) | 0.12 (4.20) | –2.46 | –3.05 | .001 | –0.52 | |||||
|
| ||||||||||||
|
| Week 2 | 0.97 (2.01) | 0.24 (1.58) | –0.72 | –2.36 | .01 | –0.41 | |||||
|
| Week 4 | 1.26 (1.53) | 0.53 (1.75) | –0.73 | –2.38 | .009 | –0.41 | |||||
|
| ||||||||||||
|
| Week 2 | 0.48 (2.25) | 0.12 (1.63) | –0.36 | –1.09 | .14 | –0.19 | |||||
|
| Week 4 | 0.73 (2.17) | 0.297 (1.76) | –0.43 | –1.28 | .10 | –0.22 | |||||
|
| ||||||||||||
|
| Week 2 | 0.596 (2.02) | 0.19 (1.64) | –0.41 | –1.29 | .10 | –0.22 | |||||
|
| Week 4 | 1.13 (1.78) | 0.31 (1.92) | –0.82 | –2.56 | .006 | –0.44 | |||||
|
| ||||||||||||
|
| Week 2 | 0.48 (2.32) | 0.32 (2.02) | –0.16 | –0.43 | .33 | –0.07 | |||||
|
| Week 4 | 0.44 (2.77) | 0.03 (2.48) | –0.41 | –0.91 | .18 | –0.16 | |||||
|
| ||||||||||||
|
| Week 1 | –0.87 (5.09) | –1.45 (4.25) | –0.58 | –0.73 | .77 | –0.13 | |||||
|
| Week 2 | –2.94 (6.84) | –2.05 (5.34) | 0.88 | 0.84 | .20 | 0.15 | |||||
|
| Week 3 | –3.55 (5.84) | –2.04 (5.77) | 1.51 | 1.51 | .07 | 0.26 | |||||
|
| Week 4 | –3.66 (5.93) | –2.68 (5.77) | 0.99 | 0.98 | .16 | 0.17 | |||||
aGAD-7: 7-item Generalized Anxiety Disorder scale.
bMISS: Minimal Insomnia Scale.
cCD-RISC: Connor-Davidson Resilience Scale.
dWHO-5: World Health Organization-5 Well-Being Index
eONS-4: Office of National Statistics Four Subjective Well-being Questions.
fPSS-10: 10-item Perceived Stress Score.
Figure 4Between-group analyses showing the change from baseline on outcome measures at each time point. Data points represent the mean and bars are standard errors. PSS-10: 10-item Perceived Stress Score; ONS-4: Office of National Statistics Four Subjective Well-being Questions; GAD-7: 7-item Generalized Anxiety Disorder scale; WHO-5: World Health Organization-5 Well-Being Index; CD-RISC: Connor-Davidson Resilience Scale; MISS: Minimal Insomnia Scale.